Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "lymphocyte count"

Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subun...

by Klaus Reither, Lynn Katsoulis, Trevor Beattie, Nicolene Gardiner, Nicole Lenz, Khadija Said, Elirehema Mfinanga, Christian Pohl, Katherine L. Fielding, Hannah Jeffery, Benjamin M. Kagina, Elisabeth J. Hughes, Thomas J. Scriba, Willem A. Hanekom, ... Plosone.org, 1 week ago

Immune modulation in acute ischemic stroke [Medical Sciences]

Peripheral lymphocytes entering brain ischemic regions orchestrate inflammatory responses, catalyze tissue death, and worsen clinical outcomes of acute ischemic stroke (AIS) in preclinical studies. However, it is not known whether modulating brain ...
 PNAS1 week ago

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Original Article Stephen M. Ansell, M.D., Ph.D., Alexander M. Lesokhin, M.D., Ivan Borrello, M.D., Ahmad Halwani, M.D., Emma C. Scott, M.D., Martin Gutierrez, M.D., Stephen J. Schuster, M.D., Michael M. Millenson, M.D., Deepika Cattry, M.S., ...
 New England Journal of Medicine2 weeks ago

REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH

Celgene Corporation ( NASDAQ:CELG ) today announced results from studies of REVLIMID ® (lenalidomide) and the combination of lenalidomide plus rituximab in patients with mantle cell lymphoma (MCL), which were presented during ...
 Franklin Credit Management Corporation1 week ago Celgene Release: REVLIMID® (Lenalidomide) Single-Agent And Combination Studies In Mantle Cell Lymphoma (MCL) Presented At American Society of Hematology  BioSpace1 week ago Combination of ISTODAX® (romidepsin) and Standard CHOP Demonstrates a Complete Response in 51% of Patients with Peripheral T-Cell Lymphoma  Morningstar.com1 week ago REVLIMID(R) (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH  Scottrade1 week ago
[x]  

IMBRUVICA® (ibrutinib) Long-term Follow-up Data in Patients Living with Relapsed/Refractory Mantle Cell Lymphoma Show Almost Half Alive at Two Years

SAN FRANCISCO and RARITAN, N.J., Dec. 8, 2014 /PRNewswire/ -- New data presented today at the American Society of Hematology (ASH) Annual Meeting in San Francisco, CA, suggest the current safety and efficacy profile for single-agent IMBRUVICA® ...
 TickerTech.com1 week ago IMBRUVICA® (ibrutinib) Shows Sustained Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia with Genetic Mutation  Wall Street Business Network1 week ago J&J -IMBRUVICA (ibrutinib) Shows Sustained Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia with Genetic Mutation  Pharmacy Choice1 week ago J&J's Janssen Reports IMBRUVICA 'Shows Sustained Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia with Genetic Mutation'  Benzinga.com1 week ago
[x]  

Seattle Genetics Presents ADCETRIS® (Brentuximab Vedotin) Data in Diffuse Large B-cell Lymphoma at ASH Annual Meeting

. (Nasdaq: SGEN) today highlighted two separate ADCETRIS (brentuximab vedotin) data presentations in relapsed/refractory and frontline diffuse large B-cell lymphoma (DLBCL) at the 56th American Society of Hematology (ASH) Annual Meeting and ...
 Reliance Trust1 week ago Seattle Genetics Presents ADCETRIS(r) (Brentuximab Vedotin) Data in...  Finwin1 week ago SEATTLE GENETICS : Presents ADCETRIS® (Brentuximab Vedotin) Data in Diffuse Large B-cell Lymphoma at ASH Annual Meeting  4 Traders1 week ago
[x]  

Gilead Presents Follow-up Data from Zydelig Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma

Gilead Sciences, Inc.( NASDAQ: GILD ) today announced long-term follow-up results from the registration studies further describing the duration of response, progression-free survival (PFS) and safety profile for Zydelig ® (idelalisib) ...
 Franklin Credit Management Corporation1 week ago Gilead Sciences, Inc. Presents Follow-Up Data From Zydelig Registrational Studies In Patients With Chronic Lymphocytic Leukemia, Follicular Lymphoma And Small Lymphocytic Lymphoma  BioSpace1 week ago Gilead Sciences : Presents Follow-up Data from Zydelig Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma  4 Traders1 week ago KINEMED : Biomarker Studies in Chronic Lymphocytic Leukemia Reveal Groundbreaking Approach for Guiding Patient Management and Drug Development  4 Traders2 weeks ago
[x]  

Hypercytotoxicity and Rapid Loss of NKp44+ Innate Lymphoid Cells during Acute SIV Infection

HIV/SIV infections break down the integrity of the gastrointestinal mucosa and lead to chronic immune activation and associated disease progression. Innate lymphoid cells (ILCs), distinguishable by high expression of NKp44 and RORγt, play key roles ...
 Plosone.org1 week ago

SMC says yes to new blood cancer drug

From today, patients in Scotland with chronic lymphocytic leukaemia (CLL) could benefit from Gazyvaro, which has been given the green light by the Scottish Medicines Consortium (SMC) for routine use on the NHS. Gazyvaro has been recommended for use ...
 Hospital Pharmacy Europe1 week ago Scottish Medicines Consortium says 'yes' to new blood cancer drug  Medical News Today1 week ago NICE reverses decision on access to new blood cancer drug  Medical News Today2 weeks ago
[x]  

ASH 2014: Paediatric leukaemia treatment regimens lead to improved outcomes in adolescents, young adults

Children and young adults with acute lymphocytic leukaemia (ALL) typically have better treatment outcomes than adults, due in part to differences in the disease, but also to higher-intensity paediatric treatment protocols. While research indicates ...
 Ecancer Medicalscience2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less